Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Garcia

Showing results (1-10 of 95) with videos related to

Pageof 10
Sort By:
Hematology. American Society of Hematology. Education Program|February 20, 2015
The target-specific oral anticoagulants: practical considerationsDavid A Garcia
Thrombosis Research|October 25, 2011
Benefits and risks of oral anticoagulation for stroke prevention in nonvalvular atrial fibrillationDavid A Garcia
Current Pharmaceutical Design|September 23, 2010
Current therapeutic strategies and future perspectives for the treatment of venous thromboembolismDavid A Garcia
Journal of Thrombosis and Thrombolysis|February 2, 2013
Patients with stable, therapeutic INR values should remain on warfarinDavid A Garcia
Hematology. American Society of Hematology. Education Program|February 20, 2015
What is the role of hemodialysis for dabigatran-associated major bleeding?Benjamin Kim, David A Garcia
Hematology. American Society of Hematology. Education Program|December 10, 2013
Should the presence of an antiphospholipid antibody affect the duration of anticoagulant treatment in patients with venous thromboembolism?David A Garcia, Wendy Lim
Annals of Internal Medicine|January 31, 2022
In high-risk inpatients with COVID-19, therapeutic- vs. standard-dose heparin reduced thromboembolism or death at 30 dBehnood Bikdeli, David A Garcia
Annals of Internal Medicine|January 31, 2022
In patients hospitalized with COVID-19, therapeutic- vs. prophylactic-dose heparin did not reduce a composite outcome at 28 dBehnood Bikdeli, David A Garcia
Cardiology Clinics|April 15, 2008
Reducing the risk for stroke in patients who have atrial fibrillationDavid A Garcia, Elaine Hylek
Clinics in Geriatric Medicine|December 27, 2005
Antithrombotic therapy in atrial fibrillationDavid A Garcia, Elaine M Hylek
Pageof 10

Showing results (1-10 of 95) with videos related to

Sort By:
Pageof 10
Hematology. American Society of Hematology. Education Program|February 20, 2015
The target-specific oral anticoagulants: practical considerationsDavid A Garcia
Thrombosis Research|October 25, 2011
Benefits and risks of oral anticoagulation for stroke prevention in nonvalvular atrial fibrillationDavid A Garcia
Current Pharmaceutical Design|September 23, 2010
Current therapeutic strategies and future perspectives for the treatment of venous thromboembolismDavid A Garcia
Journal of Thrombosis and Thrombolysis|February 2, 2013
Patients with stable, therapeutic INR values should remain on warfarinDavid A Garcia
Hematology. American Society of Hematology. Education Program|February 20, 2015
What is the role of hemodialysis for dabigatran-associated major bleeding?Benjamin Kim, David A Garcia
Hematology. American Society of Hematology. Education Program|December 10, 2013
Should the presence of an antiphospholipid antibody affect the duration of anticoagulant treatment in patients with venous thromboembolism?David A Garcia, Wendy Lim
Annals of Internal Medicine|January 31, 2022
In high-risk inpatients with COVID-19, therapeutic- vs. standard-dose heparin reduced thromboembolism or death at 30 dBehnood Bikdeli, David A Garcia
Annals of Internal Medicine|January 31, 2022
In patients hospitalized with COVID-19, therapeutic- vs. prophylactic-dose heparin did not reduce a composite outcome at 28 dBehnood Bikdeli, David A Garcia
Cardiology Clinics|April 15, 2008
Reducing the risk for stroke in patients who have atrial fibrillationDavid A Garcia, Elaine Hylek
Clinics in Geriatric Medicine|December 27, 2005
Antithrombotic therapy in atrial fibrillationDavid A Garcia, Elaine M Hylek
Pageof 10